VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Bidimensional measurable disease                   │ Bidimensional measurable disease                  │     100 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ An Eastern Cooperative Oncology Group (ECOG)       │ An Eastern Cooperative Oncology Group (ECOG)      │     100 │
│ performance status of 0 or 1                       │ performance status of 0 or 1                      │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Clinical laboratory values as specified in the     │ Clinical laboratory values as specified in the    │     100 │
│ study protocol                                     │ study protocol                                    │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Previous treatment with brentuximab vedotin        │ Previous treatment with brentuximab vedotin       │     100 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Previously received an allogeneic transplant       │ Previously received an allogeneic transplant      │     100 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known cerebral/meningeal disease including signs   │ Known cerebral/meningeal disease including signs  │     100 │
│ or symptoms of progressive multifocal              │ or symptoms of progressive multifocal             │         │
│ leukoencephalopathy (PML)                          │ leukoencephalopathy (PML)                         │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known human immunodeficiency virus (HIV) positive  │ Known human immunodeficiency virus (HIV) positive │     100 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known hepatitis B surface antigen-positive, or     │ Known hepatitis B surface antigen-positive, or    │     100 │
│ known or suspected active hepatitis C infection    │ known or suspected active hepatitis C infection   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Female participants who are lactating and          │ Female patients who are lactating and             │      95 │
│ breastfeeding or pregnant                          │ breastfeeding or pregnant                         │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Male or female participants age 18 years or older, │ Male or female patients age 18 years or older,    │      98 │
│ with relapsed or refractory sALCL who have         │ with relapsed or refractory sALCL who have        │         │
│ previously received at least 1 multiagent          │ previously received at least 1 multiagent         │         │
│ chemotherapy                                       │ chemotherapy                                      │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Male participants who agree to practice effective  │ Male patients who agree to practice effective     │      98 │
│ barrier contraception during the entire study      │ barrier contraception during the entire study     │         │
│ treatment period through 6 months after the last   │ treatment period through 6 months after the last  │         │
│ dose of study drug or agree to practice true       │ dose of study drug or agree to practice true      │         │
│ abstinence                                         │ abstinence                                        │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Female participants who are postmenopausal for at  │ Female patients who are postmenopausal for at     │      99 │
│ least 1 year before the screening visit,           │ least 1 year before the screening visit,          │         │
│ surgically sterile, or agree to practice 2         │ surgically sterile, or agree to practice 2        │         │
│ effective methods of contraception, at the same    │ effective methods of contraception, at the same   │         │
│ time, from the time of signing the informed        │ time, from the time of signing the informed       │         │
│ consent form through 30 days after the last dose   │ consent form through 30 days after the last dose  │         │
│ of study drug, or agree to practice true           │ of study drug, or agree to practice true          │         │
│ abstinence                                         │ abstinence                                        │         │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                │   Score │
╞═══════════════════════════════════════════════════╪══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                 │ Previously received an allogeneic transplant │      36 │
├───────────────────────────────────────────────────┼──────────────────────────────────────────────┼─────────┤
│ Participants with current diagnosis of primary    │ Patients with current diagnosis of primary   │      83 │
│ cutaneous anaplastic large cell lymphoma \[ALCL\] │ cutaneous ALCL (patients whose ALCL has      │         │
│ (participants whose ALCL has transformed to sALCL │ transformed to sALCL are eligible)           │         │
│ are eligible)                                     │                                              │         │
╘═══════════════════════════════════════════════════╧══════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                              │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Participants with current diagnosis of primary    │ Patients with current diagnosis of primary │      83 │
│ cutaneous anaplastic large cell lymphoma \[ALCL\] │ cutaneous ALCL (patients whose ALCL has    │         │
│ (participants whose ALCL has transformed to sALCL │ transformed to sALCL are eligible)         │         │
│ are eligible)                                     │                                            │         │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 92.8
OverAll Ratio: 94.4
